Roche announced June 27 that the U.S. FDA has issued 510(k) clearance for the company's CSF Aβ42/total-tau assay to be used for the diagnosis of Alzheimer’s disease in people aged 55 and older. The ...
Researchers with the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins University School of Medicine and four other institutions have developed a molecular test to identify the presence of brain ...
The Chosun Ilbo on MSN
Dried blood samples match CSF accuracy in Alzheimer's detection
A technology that diagnoses various diseases, including Alzheimer’s and Parkinson’s, using just a few drops of blood from a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback